Invivyd Announces Proposed Public Offering of Common Stock

Core Viewpoint - Invivyd, Inc. has initiated an underwritten public offering of its common stock, with an option for underwriters to purchase an additional 15% of the shares sold at the public offering price [1][3]. Group 1: Offering Details - The offering is subject to market conditions and there is no assurance regarding its completion or the actual size and terms [1]. - Cantor is acting as the sole book-running manager for the offering [2]. - The offering will be conducted under a shelf registration statement filed with the SEC, which was declared effective on October 5, 2022 [4]. Group 2: Use of Proceeds - Invivyd plans to use the net proceeds from the offering for trial protocol development, advancement of the VYD2311 clinical program, and research related to its pipeline programs, including RSV and measles [3]. - Additional uses of the proceeds include efforts related to monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome, as well as general corporate purposes [3]. Group 3: Company Background - Invivyd, Inc. is a biopharmaceutical company focused on providing protection against serious viral infectious diseases, starting with SARS-CoV-2 [7]. - The company utilizes a proprietary technology platform to develop and adapt antibodies, and received emergency use authorization for a monoclonal antibody in March 2024 [7].